Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

on), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

About Bayer HealthCareThe Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials.  Bayer HealthCare, a subgroup of Bayer AG with annual sales of more than EUR 15.9 billion (2009), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany.  The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions.  Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide.  Bayer HealthCare has a global workforce of 53.400 employees and is represented in more than 100 countries.  Find more information at www.bayerhealthcare.com.

Regeneron Forward Looking StatementThis news release includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties.  These include, among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
(Date:7/31/2014)... , July 31, 2014 genae, a ... industries, announced today the incorporation of genae UK in ... has one of the largest medical device markets in the ... it is projected to increase by a CAGR of 6.0% until ... equal to 9.5% of GDP. Despite recessionary pressures, market growth rates ...
(Date:7/31/2014)... AUSTIN, Texas , July 31, 2014 Vermillion, ... cancers and women,s health, will hold a conference call on ... discuss results for the second quarter ended June 30, 2014. ... to the call. Vermillion,s Chairman, President and CEO ... a question and answer period. Date: Thursday, August ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... has collaborated with the National Comprehensive Cancer Network® (NCCN®) ... ( NCCN Guidelines ™) into Elekta,s MOSAIQ® Oncology Information ... NCCN,s evidence-based clinical content directly from within the MOSAIQ ... Guidelines are widely recognized as the standard ...
... 8, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Product Development of BioMarin, will present a company update at ... June 15, 2011 at 10:00 a.m. CT.   ... conference call via the investor section of the BioMarin website, ...
Cached Medicine Technology:National Comprehensive Cancer Network Guidelines Available in Elekta's MOSAIQ EMR 2BioMarin to Present at the William Blair Growth Stock Conference 2
(Date:7/31/2014)... July 31, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
(Date:7/31/2014)... 31, 2014 Adventist Health System, ... U.S. including Florida Hospital Tampa, Florida Hospital Carrollwood, ... Hospital North Pinellas, Florida Hospital Wesley Chapel, Florida ... Florida Hospital Heartland Medical Center Lake Placid and ... list of Most Wired Hospitals and Health Systems, ...
(Date:7/31/2014)... Peninsula, MI (PRWEB) July 31, 2014 The ... preparation of the upcoming harvest. And, to celebrate, folks are ... Saturday and Sunday, September 6 and 7, 2014 along the ... festivities is an optional walk or run through the vineyards ... Winery in Suttons Bay. A unique course between rows of ...
(Date:7/31/2014)... July 31, 2014 Weblify has finally been ... years of development and testing. The result is a ... in as little as 5 minutes without knowing any HTML ... review , Shane Michaels, an SEO expert, agrees that this ... “I’ve seen a lot of web site builders out there, ...
(Date:7/31/2014)... Ohio (PRWEB) July 31, 2014 United ... of its faculty, Anthony Le Donne and Peter J. ... Also new to United is a Director of ... August 1. , Anthony Le Donne, Assistant Professor ... United Kingdom. He teaches New Testament, Second Temple Judaism, ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Florida Hospital West Florida Region is Among the Most Wired Hospitals and Health Systems in the United States 2Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3Health News:Growing Seminary Welcomes New Faculty 2
... alternative remedies more likely to misuse prescribed drugs, suffer ... Many asthma patients who use herbal remedies experience increased ... shows. , Researchers followed 326 asthma patients for 33 ... herbal remedies and used prescribed inhaled corticosteroids (ICS) less ...
... Insurance Companies Amend Policy on Radioembolization Coverage , OTTAWA, ... global leader in providing products and services for medical ... largest health insurers in the United States ... liver cancer, which includes the use of MDS Nordion,s ...
... , ... costs, boost efficiency , SILVER SPRING, Md. , ... Administration today issued guidance on Bayesian statistical methods in the ... result in less costly and more efficient patient studies. , ...
... recognized as a complication of erosive esophagitis and is ... A research team from Yokohama City University School of ... might be useful for identifying a subgroup with a ... study will be published on January 28, 2010 in ...
... Whitewater Courses and ... challenge participants with hard-to-hear truths about the responsibilities of developers who promote atop the ... designers, engineers and river scientist will take place May 24-27, 2010 in Salida, CO. ... (PRWEB) March 3, 2010 -- ...
... sugar of children, teens stable longer , THURSDAY, Feb. 4 ... teenagers with type 1 diabetes could benefit by using an ... blood sugar levels during sleep and help them control their ... issue of The Lancet , examined use of an ...
Cached Medicine News:Health News:Herbals Not the Answer for Asthma, Study Shows 2Health News:MDS Nordion's TheraSphere(R) for Unresectable Liver Cancer (HCC) Now Covered by Two Large U.S. Insurers 2Health News:MDS Nordion's TheraSphere(R) for Unresectable Liver Cancer (HCC) Now Covered by Two Large U.S. Insurers 3Health News:MDS Nordion's TheraSphere(R) for Unresectable Liver Cancer (HCC) Now Covered by Two Large U.S. Insurers 4Health News:FDA Issues Guidance to Help Streamline Medical Device Clinical Trials 2Health News:FDA Issues Guidance to Help Streamline Medical Device Clinical Trials 3Health News:Hard Green Truths - Keynotes Suggest New Value Propositions for River Park Leaders 2Health News:Artificial Pancreas Helps Type 1 Diabetics During Sleep 2
Retractable, straight double Lancet Blade, 15 Degree Angle , available in variations; Titanium handle...
10mm Tip to Bend, 0.3mm Y Tip; In Titanium....
Bend with "H" Shaped Tip, LEFT; in Titanium....
Bend with "H" Shaped Tip, Right; Stainless Steel....
Medicine Products: